Pfizer – Allergan Hook Up Could Run Into "Currency" IssuesMark Melin
When ValueWalk first reported that Allergan PLC was planning on engaging in a more aggressive roll-up strategy, citing unnamed sources in corporate meetings and confirmed by someone with visibility into the execution strategy, the speculation quickly spread as to what company was on the acquisition menu. The facts behind the exclusive reporting was later confirmed, but what many inside the financial services industry who plot the future probability paths with a mathematical precision didn . . .
This content is exclusively for paying members.
If you are subscribed and having an account error please clear cache and cookies if that does not work email firstname.lastname@example.org or click chat.